KZA 0.00% 8.0¢ kazia therapeutics limited

Ann: Change of AGM date, page-2

  1. 7,463 Posts.
    lightbulb Created with Sketch. 1263
    Interesting to note that the AGM has been pushed back to after our delisting and the three presentations at the SNO conference.


    SNO Annual Meeting (Vancouver, Canada)
    Title: Phase 1 study of paxalisib and radiotherapy for CNS disease harboring PI3K pathway mutations: pilot analysis of circulating tumor DNA for patient eligibility confirmation and post treatment response Presenter: Brandon S. Imber (Memorial Sloan Kettering Cancer Center, New York)
    Date: Friday, 17 November 2023
    Type: Poster Presentation

    SNO Annual Meeting (Vancouver, Canada)
    Title: Combining ONC201 and paxalisib for the treatment of Diffuse Midline Glioma (DIPG); the preclinical results underpinning the international Phase II clinical trial (NCT05009992)
    Presenter: Evangeline R. Jackson (University of Newcastle, Australia)
    Date: Friday, 17 November 2023
    Type: Plenary Oral Presentation

    SNO Annual Meeting (Vancouver, Canada)
    Title: PNOC022: A combination therapy trial using an adaptive platform design for patients with Diffuse Midline Gliomas (DMGs) at initial diagnosis, post-radiation therapy and at time of Progression
    Presenter: Sabine Mueller (University of California, San Francisco)
    Date: Sunday, 19 November 2023
    Type: Oral Presentation
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.